---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-070604"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:17:58.261510+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Iovance appoints Wendy Dixon to board; retains chairman Dukes after failed re-election

## Summary
- Appointed Wendy Dixon, Ph.D. to board effective June 10, 2022; granted RSU valued at $425,000 (8.30/sh).
- Chairman Iain Dukes received more withheld votes than for votes at annual meeting; board rejected his conditional resignation.
- Dukes' non-independence due to prior consulting agreement expires Dec 2022; board cited valuable contributions.
- Stockholders approved increase in 2018 Equity Plan from 14M to 20.7M shares (6.7M new shares).
- Other proposals: executive compensation (advisory) and auditor ratification passed.

## SEC filing metadata
- accession: 0001104659-22-070604
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465922070604/0001104659-22-070604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465922070604/tm2218321d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-070604
- JSON: https://secwatch.observer/filing/0001104659-22-070604.json
- Plain text: https://secwatch.observer/filing/0001104659-22-070604.txt

## Key facts
- Executive change
  Wendy Dixon was appointed as Director at IOVANCE BIOTHERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: appointed Wendy Dixon, Ph.D., as a director and new member of the Board, effective June 10, 2022, to fill such newly created vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465922070604/0001104659-22-070604-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.